Thu, Apr 24, 2014, 4:56 AM EDT - U.S. Markets open in 4 hrs 34 mins

Recent

% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • scistats scistats Apr 27, 2013 11:50 PM Flag

    Likelihood of Novartis cHTS re-up = 100%

    METHOD FOR TREATING HAEMATOLOGICAL CANCERS
    United States Patent Application 20120258940 (Zalicus cHTS used)

    KEY THERAPEUTIC TARGETS
    Novartis Oncology is developing compounds for a broad range of therapeutic targets which are
    grouped into eight categories in this Pipeline brochure:

    •RAS-RAF-MEK-ERK (extracellular signal regulated kinase) pathway inhibitors
    •Fibroblast growth factor receptor (FGFR) inhibitors

    Abstract:

    The present invention relates to a combination which comprises (a) a FGFR inhibitor and (b) a glucocorticoid receptor modulator, or a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of haematological cancers; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.

    Publication Date:10/11/2012
    Filing Date:12/17/2010

    Claims: A combination of (a) a FGFR inhibitor and (b) a modulator of glucocorticoid receptor, wherein (a) and (b) are present in each case in free form, complex form or in the form of a pharmaceutically acceptable salt.

    Novartis Oncology currently has two FGFR
    inhibitors in development: Dovitinib (TKI258) and BGJ398

    DOVITINIB
    (TKI258)

    •Phase I/II (Confirmatory) - Breast Cancer
    •Phase I/II (Confirmatory) - Endometrial cancer
    •Phase I/II (Confirmatory) - Hepatocellular carcinoma
    •Phase III or Pivotal (Registration Trials) - Renal cell carcinoma (RCC)

    Mode of Action: FGFR inhibitor
    Tumor Type: Solid

    One lung cancer patient with an FGFR1/CEP8 ratio of 2.6 by FISH analysis responded to 100 mg of NVP-BGJ398 with a 33% reduction in target lesions by CT scan at 8 weeks, confirmed at 12 weeks, and a substantial SUV decrease on PET. These observations provide early evidence that inhibition of the FGFR pathway is effective in patients with FGFR dependent cancers.

    Sentiment: Strong Buy

 
ZLCS
1.17-0.04(-3.31%)Apr 23 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.